San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)Wednesday, January 22, 2014 · 3:48 pm |
|
NovaBay: Data from Phase II Trial of Auriclosene in Urinary Catheter Blockage and Encrustation is Imminent (NBY, $1.40)Friday, September 13, 2013 · 10:46 am |
|
NovaBay: Topline Data from Two Phase IIb Trials Presents an Asymmetric Investment Opportunity in 2013 (NBY, $1.24)Monday, March 18, 2013 · 11:30 am |
|
NovaBay Swings for the Fences with NVC-422 Trial In Viral ConjunctivitisFriday, November 30, 2012 · 10:33 am |
|
Focusing on the Impetigo Indication for NVC-422 (NBY, $1.29)Monday, November 5, 2012 · 7:37 am |
|
NovaBay's Robust Clinical Pipeline Approaches Critical Clinical Trial Results in 2013Tuesday, October 30, 2012 · 7:14 am |
|
|
There are 6 reports on file. |
